The DOI matches its Crossref record.
Editorial: Bacterial pathogens, antibiotics and antibiotic resistance
Open accessAbstract
Antibiotics are arguably the most successful form of chemotherapy developed in the 20th century and perhaps over the entire history of medicine. Since their discovery and their introduction into commercial use over 70 years ago, antibiotics have saved innumerable human lives every day. Modern medicine depends on the effectiveness of antibiotics to treat and prevent various infections such as urinary tract, skin and soft tissue infections, pneumonia and also life-threatening infections such as endocarditis, meningitis and sepsis. Antibiotics are also required to maintain routine and advanced medical procedures such as cesarean sections and organ transplants. The ability of bacteria to develop resistance to antibiotics has been well documented. Initially, the arsenal of new antibiotics was sufficient to overcome the observed resistance and antibiotics were often taken for granted. However, as the pipeline of new antibiotics has decreased, bacterial resistance frequencies have continued to rise worldwide. In the last two decades, driven by the overconsumption and injudicious use of clinically used antibiotics, and the ongoing evolution and spread of mobile genetic resistance elements, increasing numbers of multidrug resistant (MDR) and even extremely drug-resistant (XDR) bacterial pathogens have emerged. These MDR bacteria increase patient morbidity, mortality and healthcare costs. In the last few years, several reports have highlighted the urgent and critical situation of antimicrobial resistance. For example, the US Centers for Disease Control and Prevention has defined antibiotic resistance as one of the world's most pressing public health problems, and it has estimated that tens of thousands of Americans already die each year from infections due to antibiotic-resistant bacteria (http://www.cdc.gov/getsmart/antibiotic-use/fast-facts.html). In the recent O’Neill report sponsored by the UK Government, it was estimated that by 2050 ∼10 million people per year would be dying from antibiotic-resistant infections. The current thematic issue of FEMS Microbiology Reviews brings together 11 reviews from expert groups that address the problems and issues associated with antibiotics and antibiotic resistance from several different angles. This includes reviews dealing with specific pathogens that show MDR and XDR and are a major cause of nosocomial infections; reviews addressing general mechanisms of antibiotic resistance such as biofilms, persistence, toxin–antitoxin systems, and the complexity of environmental and genetic modulation of resistance; and reviews dealing with new approaches to discover or develop the much needed next generation of antimicrobial agents. In February 2017, The World Health Organization (WHO) has issued a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development of new and effective antibiotic treatments. The list contains 12 bacteria and bacterial families and is divided into three categories: critical, high and medium. Enterobacteriaceae, carbapenem-resistant, ESBL-producing bacteria are listed in the critical section together with two additional pathogens. Navon-Venezia, Kondratyeva and Carattoli (2017) describe one member of this family, Klebsiella pneumoniae. Klebsiella pneumoniae is highly efficient in acquiring mutations, plasmids and genetic elements that confer antibiotic resistance. The authors provide a comprehensive overview of the evolution and diverse ‘resistome’ of this re-emerging pathogen which supports the development of MDR and XDR sequence types resulting in worldwide dissemination and outbreaks. Another pathogen listed in the WHO global priority list under the high category is Staphylococcus aureus, a common cause of nosocomial infections. Foster (2017) describes in detail the antibiotic targets and compounds commonly used to treat S. aureus infections, and the mechanisms of resistance that have been acquired. Prospects for combination therapy as well as new targets and drugs that may help in controlling infections associated with this notorious pathogen are also discussed. Prior to the era of antibiotics, Mycobacterium tuberculosis was one of the most deadly and feared of all bacterial infections. Now the spectre of untreatable drug-resistant tuberculosis is again threatening to cause a global epidemic. Gygli et al. (2017) have written a very informative and insightful review of the current understanding of intrinsic drug resistance mechanisms in M. tuberculosis, and the remarkable capability of this pathogen to evolve resistance by mutation. They argue that the measures, urgently needed to tackle this global health problem, include improving the quality of public health systems in resource-limited settings, the introduction of cost-effective point-of-care diagnostic tools, novel antimycobacterial drugs and the development of an effective vaccine. Finally, they emphasize that research needs to focu
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biofilms: Understanding the structure and contribution towards bacterial resistance in antibiotics
Shree, P., Singh, C. K., Sodhi, K. K., Surya, J. N., & Singh, D. K. (2023) · Medicine in Microecology · doi:10.1016/j.medmic.2023.100084 · Cited by 396
Metadata
- Authors
- Banin, E., Hughes, D., & Kuipers, O. P.
- Venue
- FEMS Microbiology Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-01
- Volume
- 41
- Issue
- 3
- Pages
- 450-452
- ISSN
- 0168-6445 (ISSN-L)
- 1574-6976
- OpenAlex
- W2613064815
- Cited by
- 186
- References
- 0
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Editorial: Bacterial pathogens, antibiotics and antibiotic resistance. https://app.cochat.ai/papers/10.1093/femsre/fux016
- The paper
- Banin, E., Hughes, D., & Kuipers, O. P. (2017). Editorial: Bacterial pathogens, antibiotics and antibiotic resistance. FEMS Microbiology Reviews. https://doi.org/10.1093/femsre/fux016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.